These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27241061)

  • 1. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
    Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
    Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
    Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
    Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.
    Imatoh T; Sai K; Saito Y
    J Clin Pharm Ther; 2018 Aug; 43(4):493-499. PubMed ID: 29682780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic information in drug labels: European Medicines Agency perspective.
    Ehmann F; Caneva L; Prasad K; Paulmichl M; Maliepaard M; Llerena A; Ingelman-Sundberg M; Papaluca-Amati M
    Pharmacogenomics J; 2015 Jun; 15(3):201-10. PubMed ID: 25707393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
    Schuck RN; Grillo JA
    AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of pharmacogenomics in regulatory science: a product life cycle review.
    Tan-Koi WC; Leow PC; Teo YY
    Pharmacogenomics J; 2018 May; 18(3):359-366. PubMed ID: 29205206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
    Vivot A; Boutron I; Ravaud P; Porcher R
    Genet Med; 2015 Sep; 17(9):733-8. PubMed ID: 25521333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
    Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.
    Mehta D; Uber R; Ingle T; Li C; Liu Z; Thakkar S; Ning B; Wu L; Yang J; Harris S; Zhou G; Xu J; Tong W; Lesko L; Fang H
    Drug Discov Today; 2020 May; 25(5):813-820. PubMed ID: 32032705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006-2018).
    Seo Y; Pacifici E
    Vaccine; 2020 Nov; 38(47):7485-7489. PubMed ID: 33059971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements.
    Shekhani R; Steinacher L; Swen JJ; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2020 May; 107(5):1240-1255. PubMed ID: 31715018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overdosage Section in US and EU Labeling.
    Condon S; Cantu TG; Constantinou A; Degnan EC; Lungu M; Paglione MG; Parikh SJ; Szewczyk J
    Ther Innov Regul Sci; 2024 Sep; 58(5):946-952. PubMed ID: 38886318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].
    Hafner S; Haubensak S; Paul T; Zolk O
    Dtsch Med Wochenschr; 2016 Oct; 141(21):e183-e202. PubMed ID: 27750332
    [No Abstract]   [Full Text] [Related]  

  • 16. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
    Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
    Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing recommendations for pharmacogenetic interactions related to drug metabolism.
    Filipski KK; Pacanowski MA; Ramamoorthy A; Feero WG; Freedman AN
    Pharmacogenet Genomics; 2016 Jul; 26(7):334-9. PubMed ID: 27058883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics: has the time come for pharmacists to embrace and implement the science?
    Beier MT; Panchapagesan M; Carman LE
    Consult Pharm; 2013 Nov; 28(11):696-711. PubMed ID: 24217190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.